Healthcare / Medical DevicesStockholm
$2.37
+0.13 (+5.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-55.9M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$75M
P/E
N/A
•EV/EBITDA
N/A
•ROE
273.8%
↑Gross Margin
-206.8%
↓Debt/Equity
-1.92
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-73.8%
FCF CAGR
—
FCF margin
-6631.5%
FCF / Net income
1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $324000.0 · net income $-20.6M · FCF $-21.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $324000.00 | $324000.00 | $50000.00 | $244000.00 | $18.0M |
| Net Income | $-20.6M | $-20.6M | $-55.9M | $-157.0M | $-93.1M |
| EBITDA | $-18.3M | $-18.3M | $-36.9M | $-121.8M | $-78.0M |
| EPS | -1.30 | -1.30 | -0.34 | -515.47 | -1722.14 |
| Gross Margin | -206.8% | -206.8% | -316.0% | 5997.5% | 199.6% |
| Operating Margin | -5982.7% | -5982.7% | -25856.0% | -31588.9% | -532.1% |
| Net Margin | -6345.1% | -6345.1% | -111838.0% | -64326.2% | -517.7% |
| Balance Sheet | |||||
| Debt/Equity | -1.92 | -1.92 | -6.15 | -0.88 | 0.58 |
| Current Ratio | 2.31 | 2.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-21.5M | $-21.5M | $-55.9M | $-62.0M | $-90.7M |
| Returns | |||||
| ROE | 273.8% | 273.8% | 3954.7% | 678.8% | -102.2% |
| Valuation | |||||
| P/B | — | — | — | — | 0.43 |
| Growth & Yield | |||||
| Revenue Growth | 548.0% | 548.0% | -79.5% | -98.6% | — |
| EPS Growth | -285.3% | -285.3% | 99.9% | 70.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.34 → -1.30
Residual
+14.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.